Literature DB >> 32889875

Outcomes for Physiologic Microsurgical Treatment of Secondary Lymphedema Involving the Extremity.

Maureen Beederman1, Rebecca M Garza, Shailesh Agarwal, David W Chang.   

Abstract

OBJECTIVE: The aim of this study was to examine the long-term impact of physiologic surgical options, including VLNT and LVB, on patients with secondary lymphedema of the upper or lower extremity (UEL/LEL). SUMMARY BACKGROUND DATA: VLNT and LVB have become increasingly popular in the treatment of lymphedema. However, there is a paucity of long-term data on patient outcomes after use of these techniques to treat lymphedema.
METHODS: An analysis of prospectively collected data on all patients who underwent physiologic surgical treatment of secondary lymphedema over a 5.5-year period was performed. Patient demographics, surgical details, subjective reported improvements, LLIS scores, and postoperative limb volume calculations were analyzed.
RESULTS: Two hundred seventy-four patients with secondary lymphedema (197 upper, 77 lower) were included in the study. More than 87% of UEL patients and 60% of LEL patients had reduction in excess limb volume postoperatively. At 3 months postoperatively, patients with UEL had a 31.1% reduction in volume difference between limbs, 33.9% at 6 months, 25.7% at 12 months, 47.4% at 24 months and 47.7% at 4 years. The reduction in limb volume difference followed a similar pattern but was overall lower for LEL patients. Greater than 86% of UEL and 75% of LEL patients also had improvement in LLIS scores postoperatively. Fifty-nine complications occurred (12.9%); flap survival was >99%.
CONCLUSIONS: Patients with secondary UEL/LEL who undergo VLNT/LVB demonstrate improved functional status and reduced affected limb volumes postoperatively. Patients with UEL seem to have a more substantial reduction in limb volume differential compared to LEL patients.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32889875     DOI: 10.1097/SLA.0000000000004457

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  6 in total

1.  Discussion: "Development and Psychometric Validation of a Patient-Reported Outcome Measure for Arm Lymphedema: LYMPH-Q Upper Extremity Module".

Authors:  Mark V Schaverien; Edward I Chang
Journal:  Ann Surg Oncol       Date:  2021-04-02       Impact factor: 5.344

2.  Patient-Reported Outcome Measures in Lymphedema: A Systematic Review and COSMIN Analysis.

Authors:  Mark V Schaverien; Anaeze C Offodile; Christopher Gibbons
Journal:  Ann Surg Oncol       Date:  2020-11-19       Impact factor: 5.344

3.  A Prospective Study on the Safety and Efficacy of Vascularized Lymph Node Transplant.

Authors:  Stav Brown; Babak J Mehrara; Michelle Coriddi; Leslie McGrath; Michele Cavalli; Joseph H Dayan
Journal:  Ann Surg       Date:  2022-07-15       Impact factor: 13.787

4.  Prospective Validation of Indocyanine Green Lymphangiography Staging of Breast Cancer-Related Lymphedema.

Authors:  Mads Gustaf Jørgensen; Navid Mohamadpour Toyserkani; Frederik Christopher Gulmark Hansen; Jørn Bo Thomsen; Jens Ahm Sørensen
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

5.  Indocyanine green lymphangiography is superior to clinical staging in breast cancer-related lymphedema.

Authors:  Mads Gustaf Jørgensen; Anne Pernille Hermann; Anette Riis Madsen; Steffanie Christensen; Jens Ahm Sørensen
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

6.  Adipose tissue-derived microvascular fragments promote lymphangiogenesis in a murine lymphedema model.

Authors:  Florian S Frueh; Laura Gassert; Claudia Scheuer; Andreas Müller; Peter Fries; Anne S Boewe; Emmanuel Ampofo; Claudia E Rübe; Michael D Menger; Matthias W Laschke
Journal:  J Tissue Eng       Date:  2022-07-26       Impact factor: 7.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.